Overview / Abstract: |
Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhibitors Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL Integrate patient perspectives and priorities into comprehensive care-team management of CLL |
Expiration |
Oct 22, 2022 |
Discipline(s) |
Nursing CNE, Physician CME |
Format |
Online |
Credits / Hours |
1.50 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Matthew S. Davids, MD, MMSc Associate Professor of Medicine Susan M. O’Brien, MD Associate Director for Clinical Sciences |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., BTK Inhibitors Free CE CME |